Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 randomized placebo-controlled dose-escalation study of BriLife COVID-19 vaccine in adults
MOH_2020-10-27_009446Phase 2Recruiting
- Sponsor
- Israel Institute for Biological Research
- Start
- Oct 2020
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of Brilife in coronavirus disease 2019 (COVID-19) (14 arms), sponsored by Israel Institute for Biological Research. Primary endpoints: Safety and Immunogenicity. Started Oct 2020; status: recruiting.
02
Drugs
Brilife
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2020-10-27_009446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-27_009446.